0001192482-21-000662.txt : 20210812 0001192482-21-000662.hdr.sgml : 20210812 20210812160318 ACCESSION NUMBER: 0001192482-21-000662 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20210810 FILED AS OF DATE: 20210812 DATE AS OF CHANGE: 20210812 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Fleming Alison B CENTRAL INDEX KEY: 0001640701 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37372 FILM NUMBER: 211167429 MAIL ADDRESS: STREET 1: 780 DEDHAM STREET, SUITE 800 CITY: CANTON STATE: MA ZIP: 02021 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: COLLEGIUM PHARMACEUTICAL, INC CENTRAL INDEX KEY: 0001267565 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: VA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 TECHNOLOGY CENTER DRIVE CITY: STOUGHTON STATE: MA ZIP: 02072 BUSINESS PHONE: 781-713-3699 MAIL ADDRESS: STREET 1: 100 TECHNOLOGY CENTER DRIVE CITY: STOUGHTON STATE: MA ZIP: 02072 FORMER COMPANY: FORMER CONFORMED NAME: COLLEGIUM PHARMACEUTICAL INC DATE OF NAME CHANGE: 20031020 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2021-08-10 0001267565 COLLEGIUM PHARMACEUTICAL, INC COLL 0001640701 Fleming Alison B C/O COLLEGIUM PHARMACEUTICAL, INC. 100 TECHNOLOGY CENTER DRIVE STOUGHTON MA 02072 0 1 0 0 EVP & Chief Technical Officer Common Stock 2021-08-10 4 F 0 1386 19.03 D 143694 D Shares withheld by the Issuer to satisfy applicable withholding taxes upon vesting of restricted stock units. /s/ Colleen Tupper as Attorney-In-Fact For Alison B. Fleming 2021-08-12 EX-24 2 attachment_1.htm POA

POWER OF ATTORNEY



KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and

appoints Colleen Tupper, Joseph Ciaffoni and Shirley R. Kuhlmann with

full power to act singly, as the undersigned's true and lawful attorneys

-in-fact, with full power of substitution, to:



(1)  execute for and on behalf of the undersigned, in the undersigned's

capacity as an officer and/or director and/or beneficial owner of Collegium

Pharmaceutical, Inc. (the "Company"), Forms 3, 4, and 5 in accordance with Section

16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder;



(2)  do and perform any and all acts for and on behalf of the

undersigned which may be necessary or desirable to complete and execute

any such Forms 3, 4 or 5, complete and execute any amendment or amendments

thereto and timely file such forms with the United States Securities and Exchange

Commission and any stock exchange or similar authority; and



(3)  take any other action of any type whatsoever in connection

with the foregoing which, in the opinion of such attorney-in-fact, may be of

benefit to, in the best interest of, or legally required by, the undersigned,

it being understood that the documents executed by such attorney-in-fact

on behalf of the undersigned pursuant to this Power of Attorney shall be in

such form and shall contain such terms and conditions as such attorney-in-fact

may approve in such attorney-in-fact's discretion.



The undersigned hereby grants to the attorney-in-fact full power and

authority to do and perform any and every act and thing whatsoever requisite,

necessary or proper to be done in the exercise of any of the rights and powers

herein granted, as fully to all intents and purposes as the undersigned might

or could do if personally present, with full power of substitution or revocation,

hereby ratifying and confirming all that such attorney-in-fact, or such

attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be

done by virtue of this power of attorney and the rights and powers herein

granted.



This power of attorney shall remain in full force and effect until

revoked by the undersigned in a signed writing delivered to the attorney-in-fact.



The undersigned has caused this Power of Attorney to be executed as of

the 7th day of June, 2021.



    /s/ Alison Fleming

    Name:  Alison Fleming

                                Title: Executive Vice President

           and Chief Technical Officer